US › Healthcare

Fulgent Genetics Inc (FLGT)

US · Healthcare · Diagnostics & Research

$21.85+1.02%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$85.4M

Revenue YoY

+4.4%

Net profit

$-29.5M

EPS

$-0.88

EPS estimate

$-0.79

Net margin

-34.6%

EPS came in at -0.88 against a street estimate of -0.79 — a miss of 11.4%.

Key statistics

Market cap

$553.6M

Forward P/E

7.7

P/B

0.55

Book value

$36.40

EPS (TTM)

$-2.83

52-week high

$31.04

52-week low

$13.46

50-day MA

$19.68

200-day MA

$20.61

Beta

0.93

Analyst view

Analysts rate Fulgent Genetics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $19.00.

Shareholding

Insiders

37.75%

Institutions

59.02%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.08%
RTW INVESTMENTS, LLC	4.68%
Acadian Asset Management LLC	4.48%
Vanguard Capital Management, LLC	3.20%
Dimensional Fund Advisors, Inc.	2.27%
Invenomic Capital Management, LP	2.22%
Geode Capital Management, LLC	2.12%
Ameriprise Financial Inc	2.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fulgent Genetics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.